Pharmaceutical - Markets & Marketing, UK

Filter

Current filters:

Markets & MarketingUK

Popular Filters

Pharma violates own marketing regulations, Swedish study alleges

Pharma violates own marketing regulations, Swedish study alleges

19-02-2015

A new report from Lund University in Sweden claims to show how the pharmaceutical industry, time and…

Markets & MarketingPharmaceuticalRegulationSwedenUK

England's cancer outcomes worse than rest of Europe: National Audit Office report

England's cancer outcomes worse than rest of Europe: National Audit Office report

16-01-2015

The UK’s National Audit Office has published a report, Progress in improving cancer services and outcomes…

Markets & MarketingOncologyPharmaceuticalPoliticsPricingResearchUK

UK uses fewer branded medicines per person than comparable countries and is still using older therapies

UK uses fewer branded medicines per person than comparable countries and is still using older therapies

27-11-2014

The Association of the British Pharmaceutical Industry has published new research showing that UK use…

ABPIMarkets & MarketingPharmaceuticalRegulationUK

Oncology specialists say UK's capacity crisis is impacting patient care

Oncology specialists say UK's capacity crisis is impacting patient care

21-11-2014

A survey carried out by Swiss drug major Roche has shown that frontline staff believe patient care is…

Markets & MarketingOncologyPharmaceuticalResearchRocheUK

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

Threat or promise by 2020? The FT Global Pharmaceutical and Biotechnology Conference 2014

Threat or promise by 2020? The FT Global Pharmaceutical and Biotechnology Conference 2014

19-11-2014

The Pharma Letter reports from the FT Global Pharmaceutical and Biotechnology Conference 2014.

FT Global PharmaceuticalMarkets & MarketingPharmaceuticalResearchUK

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

12-11-2014

The Health & Social Care Information Centre has published its report on the prescribing habits of the…

HumiraLucentisMarkets & MarketingNational Health ServicePharmaceuticalResearchUKUnited Kingdom

EyeForPharma Multichannel Marketing Summit 2014:

EyeForPharma Multichannel Marketing Summit 2014: "Your desk is the worst place from which to view the world"

19-09-2014

One of the key messages from the EyeForPharma Multichannel Marketing Summit in London yesterday was that…

Health Medical PharmaLEO PharmaMarkets & MarketingPharmaceuticalPharmacologySanofiUK

Latuda’s arrival better late than never for schizophrenia treatment in the UK, says analyst

12-09-2014

The recent introduction of antipsychotic drug Latuda (lurasidone) into the UK market, three years after…

Dainippon Sumitomo PharmaHealthcareLatudaMarkets & MarketingNeurologicalPharmaceuticalSunovion PharmaceuticalsUK

Pharmaceuticals, a strategic sector for the UK government

Pharmaceuticals, a strategic sector for the UK government

28-07-2014

Britain’s pharmaceuticals sector, which includes AstraZeneca and GlaxoSmithKline, two drugmakers among…

AstraZenecaEconomy of the United KingdomFinancialGlaxoSmithKlineMarkets & MarketingPharmaceuticalResearchUK

Expert View: Has UK pharma lost its Euro-vision?

Expert View: Has UK pharma lost its Euro-vision?

23-07-2014

Former AstraZeneca serialization expert, Christoph Krähenbühl, demystifies the arguments around compliance…

EuropeEuropean UnionMarkets & MarketingMedicines verification infrastructurePharmaceuticalResearchUK

GlaxoSmithKline now faces UK SFO inquiry into commercial practices

GlaxoSmithKline now faces UK SFO inquiry into commercial practices

28-05-2014

UK pharma giant GlaxoSmithKline, already subject to allegations of bribery of doctors and hospitals in…

GlaxoSmithKlineLegalMarkets & MarketingPharmaceuticalUK

UK’s MHRA seizes £8.6 million of counterfeit, controlled and unlicensed medicines

26-05-2014

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) revealed last week that it has seized…

ChinaIndiaMarkets & MarketingPharmaceuticalRegulationUK

Clinigen plans to launch Vibativ after lifting of EU marketing authorization suspension

Clinigen plans to launch Vibativ after lifting of EU marketing authorization suspension

18-03-2014

UK specialty pharma company the Clinigen Group today announced that the European Commission has ratified…

Antibiotics and Infectious diseasesClinigen GroupEuropeMarkets & MarketingPharmaceuticalRegulationTelavancin for InjectionUKVibativ

Takeda’s new diabetes drug Vipidia debuts in UK

26-02-2014

Japan’s largest drugmaker Takeda Pharmaceuticals this morning launched its new type 2 diabetes drug…

alogliptinDiabetesMarkets & MarketingNorthern EuropePharmaceuticalTakeda PharmaceuticalsUKVipidia

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Roche’s breast cancer drug Kadcyla debuts in UK

Roche’s breast cancer drug Kadcyla debuts in UK

13-02-2014

Swiss drug major Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) is now available for UK patients…

KadcylaMarkets & MarketingNorthern EuropeOncologyPharmaceuticalRocheUK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

08-01-2014

UK pharma giant GlaxoSmithKline and US partner Theravance today announced the launch of Relvar Ellipta…

GlaxoSmithKlineMarkets & MarketingNorthern EuropePharmaceuticalRelvar ElliptaRespiratory and PulmonaryTheravanceUK

UK’s CC set to keep IMS pharma data undertakings in place

UK’s CC set to keep IMS pharma data undertakings in place

26-12-2013

The UK Competition Commission (CC) has provisionally decided against varying or removing undertakings…

Markets & MarketingNorthern EuropePharmaceuticalUK

COMPANY SPOTLIGHT

Menarini

Back to top